PSTV Cytori Therapeutics Company Cash on Hand

Plus Therapeutics, Inc. (PSTV) faces risks due to a lack of consistent revenue resulting from a high dependency on the early stages of radiopharmaceutical development. Cash and cash equivalents demonstrate financial stability, with the parameter reaching 0.01. The business model relies on outsourcing production and testing to minimize capital expenditures. Plus Therapeutics, Inc. (PSTV) develops targeted isotopic agents for neuro-oncologists, targeting the nuclear medicine market.
Summary analytical data breakdowns for plustherapeutics.com (PSTV)

This indicator measures liquid capital to assess the business's capacity for autonomous development without external borrowing. By analyzing cash resources totaling 0.01, an investor can diagnose the risk of funding shortages; for Plus Therapeutics, Inc. (PSTV), this is critical, as uncertainty regarding clinical data for radiopharmaceuticals forces the company to cover cash flow gaps through dilutive secondary offerings.